77th OREGON LEGISLATIVE ASSEMBLY – 2013 Regular Session STAFF MEASURE SUMMARY Senate Committee on Health Care & Human Services

REVENUE: No revenue impact	
ETGCAT M' ' 10° 1'	

FISCAL: Minimal fiscal impact, no statement issued			
Action:		Do Pass as Amended and Be Printed Engrossed	
Vote:		4 - 0 - 1	
	Yeas:	Knopp, Kruse, Shields, Monnes Anderson	
	Nays:	0	
	Exc.:	Steiner Hayward	
Prepared By:		Sandy Thiele-Cirka, Administrator	
Meeting Dates:		3/19, 4/15	

WHAT THE MEASURE DOES: Modifies meeting requirements for Oregon Health Authority's Pharmacy and Therapeutics Committee (P&T Committee). Requires P&T Committee to divide agenda into two separate sections (P&T business and Drug Utilization Reviews section). Specifies required committee findings shall be by majority vote. Deletes undefined term "other reimbursements". Declares emergency, effective on passage.

ISSUES DISCUSSED:

- Current P&T Committee and Drug Utilization Review (DUR)process
- Separating sessions on agenda
- P&T executive session
- Transparency and public process
- Prior authorization and best practices
- Affordable Care Act and transition process
- Proposed amendment

EFFECT OF COMMITTEE AMENDMENT: Requires Pharmacy and Therapeutics Committee (P&T Committee) to divide agenda into two separate sections (P&T business and Drug Utilization Reviews section). Specifies that required committee findings shall be by majority vote. Deletes undefined term "other reimbursements".

BACKGROUND: In 2011, House Bill 2100 was enacted, in part, to consolidate the functions of the Drug Use Review Board (DUR) and the Health Services Commission (HSC) into an 11-member Pharmacy and Therapeutics Committee (P&T Committee). The P&T Committee is charged with performing drug class reviews and developing policy recommendations relating to drug use and utilization for the Oregon Health Authority's Medical Assistance Program. During the 2011 deliberations on House Bill 2100, the House Health Care Committee Co-Chairs directed stakeholders to meet and develop amendments and consensus on the measure.

Senate Bill 777-A builds on that consensus and implements additional measures to increase transparency and clarification in the medication review process.